SrasV1, PubMed, Corpus, bibRecord, 000F69

Antiviral drugs specific for coronaviruses in preclinical development.

Identifieur interne : 000F69 ( PubMed/Corpus ); précédent : 000F68; suivant : 000F70

Antiviral drugs specific for coronaviruses in preclinical development.

Auteurs : Adeyemi O. Adedeji ; Stefan G. Sarafianos

Source :

Current opinion in virology [ 1879-6265 ] ; 2014.

RBID : pubmed:24997250

English descriptors

KwdEn :
- Antiviral Agents (isolation & purification), Antiviral Agents (pharmacology), Drug Discovery (trends), Drug Evaluation, Preclinical, Humans, Middle East Respiratory Syndrome Coronavirus (drug effects), SARS Virus (drug effects).
MESH :
- chemical , isolation & purification : Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- drug effects : Middle East Respiratory Syndrome Coronavirus, SARS Virus.
- trends : Drug Discovery.
- Drug Evaluation, Preclinical, Humans.

Abstract

Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics.

DOI: 10.1016/j.coviro.2014.06.002
PubMed: 24997250

Links to Exploration step

pubmed:24997250

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral drugs specific for coronaviruses in preclinical development.</title>
<author><name sortKey="Adedeji, Adeyemi O" sort="Adedeji, Adeyemi O" uniqKey="Adedeji A" first="Adeyemi O" last="Adedeji">Adeyemi O. Adedeji</name>
<affiliation><nlm:affiliation>Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616, United States. Electronic address: aoadedeji@ucdavis.edu.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G" last="Sarafianos">Stefan G. Sarafianos</name>
<affiliation><nlm:affiliation>Christopher Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, United States; Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, MO 65211, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States. Electronic address: sarafianoss@missouri.edu.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24997250</idno>
<idno type="pmid">24997250</idno>
<idno type="doi">10.1016/j.coviro.2014.06.002</idno>
<idno type="wicri:Area/PubMed/Corpus">000F69</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F69</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral drugs specific for coronaviruses in preclinical development.</title>
<author><name sortKey="Adedeji, Adeyemi O" sort="Adedeji, Adeyemi O" uniqKey="Adedeji A" first="Adeyemi O" last="Adedeji">Adeyemi O. Adedeji</name>
<affiliation><nlm:affiliation>Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616, United States. Electronic address: aoadedeji@ucdavis.edu.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sarafianos, Stefan G" sort="Sarafianos, Stefan G" uniqKey="Sarafianos S" first="Stefan G" last="Sarafianos">Stefan G. Sarafianos</name>
<affiliation><nlm:affiliation>Christopher Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, United States; Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, MO 65211, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States. Electronic address: sarafianoss@missouri.edu.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Current opinion in virology</title>
<idno type="eISSN">1879-6265</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (isolation & purification)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Drug Discovery (trends)</term>
<term>Drug Evaluation, Preclinical</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term>
<term>SARS Virus (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Discovery</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Evaluation, Preclinical</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24997250</PMID>
<DateCompleted><Year>2015</Year>
<Month>06</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-6265</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>8</Volume>
<PubDate><Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Current opinion in virology</Title>
<ISOAbbreviation>Curr Opin Virol</ISOAbbreviation>
</Journal>
<ArticleTitle>Antiviral drugs specific for coronaviruses in preclinical development.</ArticleTitle>
<Pagination><MedlinePgn>45-53</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.coviro.2014.06.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1879-6257(14)00137-0</ELocationID>
<Abstract><AbstractText>Coronaviruses are positive stranded RNA viruses that cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses impeded the development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV), and more recently, Middle East respiratory syndrome coronavirus (MERS-CoV), has impelled the development of such drugs. This review focuses on some newly identified SARS-CoV inhibitors, with known mechanisms of action and their potential to inhibit the novel MERS-CoV. The clinical development of optimized versions of such compounds could be beneficial for the treatment and control of SARS-CoV, the current MERS-CoV and other future SARS-like epidemics. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adedeji</LastName>
<ForeName>Adeyemi O</ForeName>
<Initials>AO</Initials>
<AffiliationInfo><Affiliation>Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616, United States. Electronic address: aoadedeji@ucdavis.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sarafianos</LastName>
<ForeName>Stefan G</ForeName>
<Initials>SG</Initials>
<AffiliationInfo><Affiliation>Christopher Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, United States; Department of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia, MO 65211, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States. Electronic address: sarafianoss@missouri.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>AI100890</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P50 GM103368</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>GM103368</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI076119</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI100890</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI099284</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI099284</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 AI112417</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI076119</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI112417</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Curr Opin Virol</MedlineTA>
<NlmUniqueID>101560941</NlmUniqueID>
<ISSNLinking>1879-6257</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004353" MajorTopicYN="Y">Drug Evaluation, Preclinical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>04</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>05</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>06</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>7</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>7</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24997250</ArticleId>
<ArticleId IdType="pii">S1879-6257(14)00137-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.coviro.2014.06.002</ArticleId>
<ArticleId IdType="pmc">PMC4195804</ArticleId>
<ArticleId IdType="mid">NIHMS606468</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Bioorg Med Chem. 2010 Nov 15;18(22):7849-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20947359</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Mar;53(3):1013-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19114674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Soc Trans. 2011 Oct;39(5):1371-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21936817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Antibodies. 2005;14(3-4):81-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16720978</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Dec;79(24):15189-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16306590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Aug;77(16):8801-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885899</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Sep;74(17):8127-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10933723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2004 Dec;44(6):903-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15492138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2005 Jun 30;48(13):4469-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15974598</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2009;69(1):31-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19192935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2001 Jul;75(14):6676-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11413334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Virus Res. 2005;65:147-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16387196</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14651994</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(12):e28479</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22164298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Jun;80(11):5563-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16699037</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2009 Jun;7(6):439-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19430490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2011 Nov;92(2):187-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21820471</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Prog Med Chem. 2005;43:239-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15850827</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2009 Feb 4;583(3):549-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19166843</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Biol. 1995 Oct;131(2):339-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7593163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Biol. 2005 Oct;3(10):e324</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16128623</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Oct;19(10):1697-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24050621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2012;3(6). pii: e00473-12. doi: 10.1128/mBio.00473-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2005 Sep 1;13(17):5240-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15994085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2012 Jun;94(3):288-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22265858</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2009 Mar 15;19(6):1636-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19233643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 May;77(9):5054-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12692208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Med Chem. 2006;6(4):361-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16611148</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(5):e36521</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22615777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2000 May;81(Pt 5):1335-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10769077</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 May 14;279(20):20836-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14996844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Ther. 2008 Jul;30(7):1228-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18691983</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Jul 9;319(4):1216-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2007;315:325-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17848070</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2013 May;94(Pt 5):1028-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23364191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2008 Apr 15;16(8):4652-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18329272</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4894-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841268</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs R D. 1999 Nov;2(5):347-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10728478</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Dec;78(24):13600-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15564471</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2006 Mar 3;98(4):463-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16514079</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2012 Sep;56(9):4718-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22733076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2008 Jul 15;47(2):236-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18532888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Virol. 2012 Feb;2(1):50-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22440966</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Biol. 2006 Mar;13(3):261-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16638531</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Biol. 2005 Mar;12(3):303-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15797214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Future Virol. 2011 May;6(5):615-631</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21765859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Feb;82(4):1819-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18057240</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2007 Nov 27;581(28):5454-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17981158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2013 Mar;19(3):456-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23622767</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 Jun 15;49(12):3485-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16759091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Feb;14(2):140-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24355866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Future Med Chem. 2013 Dec;5(18):2119-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24261888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Med Chem. 2011 Nov;46(11):5698-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21925774</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 May 4;49(9):2703-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16640330</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2305-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12917450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2014 Jul;159(7):1575-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24515532</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2000 Jun 16;272(3):699-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10860818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2004 Sep 10;574(1-3):116-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15358550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2013;3:1686</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Jul;87(14):8017-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23678171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2010 Jun 15;20(12):3569-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20494577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2005 Aug 15;339(1):136-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15992849</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2004 May;59(5):414-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15115870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15226499</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Biol. 2001 Jul;8(7):645-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11451666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chembiochem. 2007 Sep 24;8(14):1654-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17722121</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Pharmacol. 2010 Aug;78(2):319-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20466822</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2003 Dec 12;115(6):652-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14675530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Sep;74(18):8358-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10954535</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Resist Updat. 2004 Apr;7(2):89-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15158765</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F69 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000F69 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:24997250
   |texte=   Antiviral drugs specific for coronaviruses in preclinical development.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:24997250" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Antiviral drugs specific for coronaviruses in preclinical development.

Antiviral drugs specific for coronaviruses in preclinical development.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki